A detailed history of Lazard Asset Management LLC transactions in United Therapeutics Corp stock. As of the latest transaction made, Lazard Asset Management LLC holds 115,251 shares of UTHR stock, worth $31.7 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
115,251
Previous 197,073 41.52%
Holding current value
$31.7 Million
Previous $43.3 Million 38.91%
% of portfolio
0.03%
Previous 0.06%

Shares

34 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$210.76 - $249.51 $17.2 Million - $20.4 Million
-81,822 Reduced 41.52%
115,251 $26.5 Million
Q4 2023

Feb 14, 2024

BUY
$214.88 - $256.94 $8.91 Million - $10.6 Million
41,445 Added 26.63%
197,073 $43.3 Million
Q3 2023

Nov 14, 2023

SELL
$211.82 - $248.24 $2 Million - $2.34 Million
-9,441 Reduced 5.72%
155,628 $35.2 Million
Q2 2023

Aug 14, 2023

BUY
$205.19 - $232.99 $5.58 Million - $6.34 Million
27,192 Added 19.72%
165,069 $36.4 Million
Q1 2023

May 15, 2023

BUY
$212.99 - $276.17 $4.77 Million - $6.19 Million
22,398 Added 19.4%
137,877 $30.9 Million
Q4 2022

Feb 14, 2023

SELL
$205.95 - $280.43 $10.1 Million - $13.8 Million
-49,058 Reduced 29.82%
115,479 $32.1 Million
Q3 2022

Nov 14, 2022

SELL
$203.3 - $244.17 $5.22 Million - $6.27 Million
-25,677 Reduced 13.5%
164,537 $34.5 Million
Q2 2022

Aug 09, 2022

SELL
$174.81 - $241.14 $7.31 Million - $10.1 Million
-41,813 Reduced 18.02%
190,214 $44.8 Million
Q1 2022

May 13, 2022

SELL
$166.16 - $213.96 $11.8 Million - $15.2 Million
-71,272 Reduced 23.5%
232,027 $41.6 Million
Q4 2021

Feb 09, 2022

SELL
$184.32 - $216.08 $2.62 Million - $3.07 Million
-14,218 Reduced 4.48%
303,299 $65.5 Million
Q3 2021

Nov 15, 2021

SELL
$179.86 - $214.88 $6.55 Million - $7.83 Million
-36,419 Reduced 10.29%
317,517 $58.6 Million
Q2 2021

Aug 12, 2021

BUY
$170.47 - $211.93 $8.46 Million - $10.5 Million
49,613 Added 16.3%
353,936 $63.5 Million
Q1 2021

May 14, 2021

BUY
$153.94 - $174.85 $9.01 Million - $10.2 Million
58,532 Added 23.81%
304,323 $50.9 Million
Q4 2020

Feb 11, 2021

BUY
$101.87 - $151.79 $3.15 Million - $4.7 Million
30,955 Added 14.41%
245,791 $37.3 Million
Q3 2020

Nov 13, 2020

BUY
$99.9 - $121.13 $333,865 - $404,816
3,342 Added 1.58%
214,836 $21.7 Million
Q2 2020

Aug 13, 2020

BUY
$92.74 - $125.82 $19.6 Million - $26.6 Million
211,494 New
211,494 $25.6 Million
Q2 2019

Aug 14, 2019

SELL
$76.06 - $120.81 $751,396 - $1.19 Million
-9,879 Closed
0 $0
Q1 2019

May 13, 2019

SELL
$107.15 - $126.84 $33,859 - $40,081
-316 Reduced 3.1%
9,879 $1.16 Million
Q3 2018

Nov 13, 2018

BUY
$113.81 - $129.46 $1.16 Million - $1.32 Million
10,195 New
10,195 $1.3 Million
Q1 2018

May 14, 2018

SELL
$107.21 - $151.94 $1,822 - $2,582
-17 Closed
0 $0
Q4 2017

Aug 28, 2019

SELL
$118.58 - $151.28 $3,557 - $4,538
-30 Reduced 63.83%
17 $2,000
Q4 2017

Feb 13, 2018

BUY
$118.58 - $151.28 $3,557 - $4,538
30 Added 176.47%
47 $6,000
Q3 2017

Aug 19, 2019

SELL
$114.6 - $136.81 $2,292 - $2,736
-20 Reduced 54.05%
17 $1,000
Q3 2017

Nov 13, 2017

BUY
$114.6 - $136.81 $2,177 - $2,599
19 Added 105.56%
37 $4,000
Q2 2017

Aug 19, 2019

SELL
N/A
-37,443 Reduced 99.95%
18 $2,000
Q1 2017

Aug 13, 2019

SELL
N/A
-56,018 Reduced 59.93%
37,461 $5.07 Million
Q4 2016

Jul 30, 2019

BUY
N/A
6,298 Added 7.22%
93,479 $13.4 Million
Q3 2016

Aug 07, 2019

BUY
N/A
3,700 Added 4.43%
87,181 $10.3 Million
Q2 2016

Jul 29, 2019

SELL
N/A
-159,607 Reduced 65.66%
83,481 $8.84 Million
Q1 2016

Jul 25, 2019

BUY
N/A
48,537 Added 24.95%
243,088 $27.1 Million
Q4 2015

Jul 24, 2019

BUY
N/A
49,334 Added 33.97%
194,551 $30.5 Million
Q3 2015

Jul 15, 2019

SELL
N/A
-124,977 Reduced 46.25%
145,217 $19.1 Million
Q2 2015

Jul 08, 2019

BUY
N/A
158,823 Added 142.61%
270,194 $47 Million
Q4 2014

Aug 29, 2019

BUY
N/A
111,371
111,371 $14.4 Million

Others Institutions Holding UTHR

About UNITED THERAPEUTICS Corp


  • Ticker UTHR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,516,300
  • Market Cap $12.5B
  • Description
  • United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...
More about UTHR
Track This Portfolio

Track Lazard Asset Management LLC Portfolio

Follow Lazard Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lazard Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lazard Asset Management LLC with notifications on news.